Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 8/20 | 0.47 |
| ▸ | DYRK1B | Q9Y463 | 7/20 | 0.47 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CCNE1 | P24864 | 3/20 | 0.38 |
| ▸ | CDK2 | P24941 | 3/20 | 0.38 |
| ▸ | IGF1R | P08069 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | NAMPT | P43490 | 1/20 | 0.36 |
| ▸ | CKS1B | P61024 | 1/20 | 0.35 |
| ▸ | SKP1 | P63208 | 1/20 | 0.35 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.35 |
| ▸ | BRAF | P15056 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10323582 | 0.89 | DYRK1A (0.48) | DYRK1ADYRK1BLMNASMN1; SMN2TP53 | |
| SCHEMBL10323238 | 0.87 | DYRK1A (0.64) | DYRK1ADYRK1BMAPK8 | |
| SCHEMBL11304261 | 0.87 | DYRK1A (0.49) | DYRK1ADYRK1BTP53BRAF | |
| SCHEMBL10324084 | 0.84 | DYRK1A (0.48) | DYRK1ADYRK1BMAPK8LMNASMN1; SMN2 | |
| SCHEMBL10324514 | 0.84 | DYRK1A (0.49) | DYRK1ADYRK1BLMNATP53 | |
| SCHEMBL10323484 | 0.83 | DYRK1A (0.51) | DYRK1ADYRK1BMAPK8IGF1RCYP3A4 | |
| SCHEMBL11952854 | 0.82 | DYRK1A (0.63) | DYRK1ADYRK1B | |
| SCHEMBL10323504 | 0.81 | DYRK1A (0.43) | DYRK1ADYRK1BMAPK8IGF1RCYP3A4 | |
| SCHEMBL10323719 | 0.79 | DYRK1A (0.49) | DYRK1ADYRK1BLMNASMN1; SMN2 | |
| SCHEMBL10446982 | 0.76 | DYRK1A (0.66) | DYRK1ADYRK1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012098065-A1 | PYRIDO PYRIMIDINES FOR USE AS DYRK1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-07-26 | — | — | WO | disclosed |
| US-20120184542-A1 | PYRIDO PYRIMIDINES | ANDERSON KEVIN (US) | 2012-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120184542-A1 | PYRIDO PYRIMIDINES | TYMS, TYMP, DPYD | DYRK1A 654/4885DYRK1B 570/4885MAPK8 2282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.